<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-93576" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Chronic Headaches</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Murphy</surname>
            <given-names>Christie</given-names>
          </name>
          <aff>Ohio Health</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hameed</surname>
            <given-names>Sajid</given-names>
          </name>
          <aff>Aga Khan University Hospital</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Christie Murphy declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sajid Hameed declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>31</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-93576.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Chronic headache is not a single disease entity but an umbrella term that encompasses all chronic headaches. The International Headache Society defines chronic daily headaches (CDH) as "15 or more headache episodes per month for at least three months." A chronic daily headache can be divided into primary and secondary headache disorders depending upon its etiology. Primary chronic headache disorders do not have secondary organic etiology. Within the primary headache categories, a headache duration of fewer than 4 hours is labeled as a 'short headache .' More than 4 hours is known as a 'long headache.' Long headaches more commonly include chronic migraine and chronic tension headaches. There are a variety of causes and ways to manage this condition. This activity reviews the evaluation and treatment of chronic headaches and explains the role of the interprofessional team in evaluating, treating, managing, and improving care for patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of chronic headaches.</p></list-item><list-item><p>Outline the appropriate evaluation of chronic headaches.</p></list-item><list-item><p>Review the management options available for chronic headaches.</p></list-item><list-item><p>Describe interprofessional team strategies for improving care coordination and communication to advance chronic headaches and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=93576&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=93576">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-93576.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Chronic headache is not a single disease entity but an umbrella term that encompasses all chronic headaches. The International Headache Society defines chronic daily headaches (CDH) as <italic toggle="yes">"15 or more headache episodes per month for at least three months."</italic><xref ref-type="bibr" rid="article-93576.r1">[1]</xref>&#x000a0;Chronic headaches are&#x000a0;not an official class in the International Classification of Headache Disorders (ICHD).<xref ref-type="bibr" rid="article-93576.r2">[2]</xref>&#x000a0;</p>
        <p>CDH is rather a descriptive term that most encompasses five subtypes of primary and secondary headaches defined by ICHD-3:</p>
        <list list-type="bullet">
          <list-item>
            <p>Chronic migraine headache</p>
          </list-item>
          <list-item>
            <p>Chronic tension-type headache</p>
          </list-item>
          <list-item>
            <p>Medication overuse headache (MOH)</p>
          </list-item>
          <list-item>
            <p>Hemicrania continua</p>
          </list-item>
          <list-item>
            <p>New daily persistent headache</p>
          </list-item>
        </list>
        <p>A chronic daily headache can be divided into primary and secondary headache disorders depending upon its etiology. Primary chronic headache disorders do not have secondary organic etiology. Within the primary headache categories, a headache duration of&#x000a0;fewer than 4 hours is labeled as a <italic toggle="yes">'short headache .'</italic>&#x000a0;More than 4 hours is known as a <italic toggle="yes">'long headache.'</italic> Long headaches more commonly include chronic migraine and chronic tension headaches.<xref ref-type="bibr" rid="article-93576.r1">[1]</xref>&#x000a0;Secondary headaches can occur due to&#x000a0;secondary causes such as medication overuse, intracranial tumors, central nervous system (CNS) infections, raised intracranial pressure, metabolic abnormalities, post-traumatic, vascular, and structural pathologies.<xref ref-type="bibr" rid="article-93576.r3">[3]</xref>&#x000a0;It is important to realize that chronic headaches are often caused by a multifactorial combination of&#x000a0;the causes mentioned above and can occur along a continuum.</p>
      </sec>
      <sec id="article-93576.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The International Classification of Headache Disorders (ICHD)&#x000a0;recognizes over 200 headache disorders and divides them into three groups, which are primary, secondary, and painful cranial neuropathies.<xref ref-type="bibr" rid="article-93576.r4">[4]</xref>&#x000a0;The ICHD system is hierarchical, with multiple&#x000a0;subtypes within each main headache type.</p>
        <p>All chronic headaches meet the criteria of occurring at least 15 times a month for at least three months, but both primary and secondary chronic headaches have unique characteristics.</p>
        <p>Primary headaches lasting more than four hours include chronic&#x000a0;migraines, tension headaches, persistent daily headaches, and hemicrania continua.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Chronic migraine has typical features of being unilateral, pulsatile, moderate to severe, and may or may not have an aura.<xref ref-type="bibr" rid="article-93576.r4">[4]</xref>&#x000a0;Episodic migraines may evolve into chronic migraines.</p>
          </list-item>
          <list-item>
            <p>Chronic migraine&#x000a0;in children and adolescents is often bilateral, and associated symptoms such as photophobia and phonophobia&#x000a0;are often inferred from behavior.<xref ref-type="bibr" rid="article-93576.r5">[5]</xref></p>
          </list-item>
          <list-item>
            <p>Chronic headaches, which are bilateral, non-pulsatile, and lack associated symptoms, are classified as chronic tension headaches.<xref ref-type="bibr" rid="article-93576.r4">[4]</xref>&#x000a0;Pericranial tenderness&#x000a0;is often found on palpation.</p>
          </list-item>
          <list-item>
            <p>A new persistent daily headache (NDPH) occurs suddenly and becomes&#x000a0;unremitting within 24 hours of onset. Patients typically have no prior history of headaches. NDPH is rare and refractory to treatment.<xref ref-type="bibr" rid="article-93576.r6">[6]</xref></p>
          </list-item>
          <list-item>
            <p>Hemicrania continua is unilateral, has autonomic symptoms, and is continuous with exacerbations. Responsiveness to indomethacin helps distinguish this form of headache.</p>
          </list-item>
        </list>
        <p>Primary headaches lasting less than four hours include chronic cluster headaches, neuralgiform headache attacks, and primary stabbing headaches.</p>
        <list list-type="bullet">
          <list-item>
            <p>Chronic cluster headache varies from the acute form in that there are no remissions, and headaches must occur over at least one year. Headaches are unilateral in the trigeminal distribution and associated with unilateral autonomic symptoms. Patients often experience agitation during the headache.</p>
          </list-item>
          <list-item>
            <p>The short-lasting neuralgiform headaches include short-lasting unilateral neuralgiform headache attacks with&#x000a0;conjunctival injection and tearing (SUNCT)&#x000a0;and short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA). Both types have severe, unilateral pain associated with autonomic symptoms. In addition, SUNCT has both lacrimation and conjunctival injection. SUNA may have either but not both of those features and may be accompanied by rhinorrhea or nasal congestion.</p>
          </list-item>
          <list-item>
            <p>Primary stabbing headaches may frequently occur throughout the day. Sharp, sudden, jabbing pain occurs in the temporal or peri-orbital regions.</p>
          </list-item>
        </list>
        <p>Secondary chronic daily headaches include medication overuse, CNS infection, CNS hematomas, intracranial tumor, raised intracranial pressure, low-pressure headache, vasculitis, aneurysms, and cerebrospinal fluid (CSF) leak.<xref ref-type="bibr" rid="article-93576.r2">[2]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Chronic medication overuse headaches often overlap with other acute and chronic headache types. Analgesics are widely used for symptom control in migraine and tension headaches. Patients inadvertently increase headache frequency by overuse of analgesics. The ICHD further classifies this disorder based on the medications used, including NSAIDs, triptans, ergotamines, non-opioid, and opioid analgesics.<xref ref-type="bibr" rid="article-93576.r7">[7]</xref>&#x000a0;Withdrawal of analgesics typically worsens these headaches.</p>
          </list-item>
          <list-item>
            <p>The remainder of the secondary chronic headache etiologies is beyond the scope of this article.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-93576.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Headache disorders have a large global burden. Both acute and chronic headaches are most prevalent between the teenage years and the fifth decade.<xref ref-type="bibr" rid="article-93576.r8">[8]</xref></p>
        <p>Chronic headaches occur in 1 to 4% of the entire population.<xref ref-type="bibr" rid="article-93576.r9">[9]</xref>&#x000a0;Approximately 39 million people in the United States and 1 billion people worldwide are affected. Of patients seen in a headache clinic, 40% are diagnosed with chronic headaches. Prevalence rates&#x000a0;in women are 3 to 5 times higher than in men.<xref ref-type="bibr" rid="article-93576.r4">[4]</xref></p>
        <p>Chronic migraines are associated with significant comorbidities, including obesity, obstructive sleep apnea, depression, chronic pain disorders, and cardiovascular disease.<xref ref-type="bibr" rid="article-93576.r10">[10]</xref></p>
        <p>Chronic migraine headaches also have a prevalence of 7 to 17% in children and adolescents.<xref ref-type="bibr" rid="article-93576.r5">[5]</xref>&#x000a0;The prevalence is equal between boys and girls until age 12, when females predominate.</p>
        <p>Hemicrania continua is less common than chronic migraine or tension headache. It has a 2&#x000a0;to 1 female to male incidence, with the peak diagnosis occurring in the third decade.</p>
        <p>Chronic cluster headache occurs more often in men but is also experienced by women. Women often have nausea and vomiting associated with chronic cluster headaches and may be initially diagnosed with migraine headaches.<xref ref-type="bibr" rid="article-93576.r11">[11]</xref></p>
      </sec>
      <sec id="article-93576.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Although the pathophysiology of each type of chronic headache varies, shared features include sensitization of the trigeminal system, alterations in brain structure and function, and environmental factors.<xref ref-type="bibr" rid="article-93576.r12">[12]</xref>&#x000a0;Most chronic headaches result from the transformation of an episodic headache disorder.&#x000a0;</p>
        <p>Modifiable risk factors, including sleep disorders, obesity, and high caffeine consumption, increase the chance of headache transformation from episodic to chronic headaches.</p>
        <p>Serotonin, which has vasoconstrictive and anti-inflammatory effects, is a therapeutic target of triptans in migraines.</p>
        <p>Serotonin, released from the brainstem serotonergic nuclei, may play a role in migraine; however, the exact role of its mechanisms remains a matter of controversy. Most likely, serotonin levels are low between attacks because it may cause a deficiency in the serotonin pain inhibition system, therefore helping the activation of the trigeminal system. It could mediate by acting directly over the cranial vessels, in central pain control pathways, or by cortical projections of brainstem serotonergic nuclei.<xref ref-type="bibr" rid="article-93576.r13">[13]</xref><xref ref-type="bibr" rid="article-93576.r14">[14]</xref></p>
        <p>Calcitonin gene-related peptide is abundant in trigeminal ganglion neurons. It is released from the peripheral and central nerve terminals and secreted within the trigeminal ganglion. When released from the peripheral terminals, it initiates an increased synthesis of nitric oxide and later sensitization of trigeminal nerves.<xref ref-type="bibr" rid="article-93576.r15">[15]</xref><xref ref-type="bibr" rid="article-93576.r16">[16]</xref>&#x000a0;It is a strong vasodilator of cerebral and dura mater vessels, therefore a component of neurogenic inflammation. It also mediates trigeminal pain transmission from vessels to the central nervous system.</p>
        <p>Medication overuse headaches share much of the pathophysiology of migraine and tension headaches as functional and structural changes in the central nervous system. Changes in the serotonergic neuromodulatory system and upregulation of vasoactive and pro-inflammatory mediators also contribute.<xref ref-type="bibr" rid="article-93576.r7">[7]</xref>&#x000a0;The condition exhibits both functional and structural changes in the central nervous system (CNS), particularly the hippocampal periaqueductal gray area, posterior cingulate cortex thalamus, cerebellum, and orbitofrontal cortex (OFC), and the mesocorticolimbic reward system.<xref ref-type="bibr" rid="article-93576.r17">[17]</xref><xref ref-type="bibr" rid="article-93576.r18">[18]</xref>&#x000a0;Also found were changes in the serotonergic neuromodulatory system, upregulation of vasoactive and pro-inflammatory mediators, increased susceptibility to cortical spreading depression, central sensitization, and an increase in nociceptive sensory fields.<xref ref-type="bibr" rid="article-93576.r19">[19]</xref>&#x000a0;Some studies have theorized a potential genetic risk as to the etiology of the development of MOH. One such model is the renin-angiotensin system, known to have an active role in regulating neural plasticity.<xref ref-type="bibr" rid="article-93576.r20">[20]</xref></p>
        <p>Trigeminal autonomic cephalalgias, cluster headache, SUNCT, SUNA, and hemicrania continua, have complex pathogenesis. Severe pain and autonomic symptoms are attributed to the trigeminal autonomic reflex via pain-producing innervation and cranial parasympathetic activation.<xref ref-type="bibr" rid="article-93576.r21">[21]</xref></p>
      </sec>
      <sec id="article-93576.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>A&#x000a0;thorough history and physical exam are indispensable in the diagnosis of chronic daily headaches. As noted above, a chronic headache should have 15 or more monthly episodes for at least three months. One should determine the frequency, intensity, and characteristics&#x000a0;of the pain, as well as the aggravating and alleviating factors.&#x000a0;Many headache types involve ipsilateral autonomic symptoms such as lacrimation, conjunctival injection, conjunctival edema, ptosis, miosis, nasal congestion, rhinorrhea, etc.</p>
        <p>A thorough medication reconciliation, including over-the-counter analgesics, is essential.&#x000a0;Patients with medication-overuse headaches often have a primary headache disorder, and they frequently use pain medications.<xref ref-type="bibr" rid="article-93576.r22">[22]</xref>&#x000a0;Medication classes may include non-steroidal anti-inflammatory drugs (NSAIDs), triptans, ergotamines, opioids, or a combination of multiple analgesics. Key historical features include morning headaches, the onset of headaches when medication is delayed, and relief when medication is taken.<xref ref-type="bibr" rid="article-93576.r23">[23]</xref></p>
        <p>Comorbidities, sleep history, and a family history of headaches should also be noted.&#x000a0;A&#x000a0;secondary headache disorder should be excluded from the history and examination.&#x000a0;</p>
        <p>Recognition of headache "red flags" is critical in identifying secondary headaches and ordering additional diagnostic testing. Those "red flags" include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Age above 50</p>
          </list-item>
          <list-item>
            <p>A significant change in prior headache pattern</p>
          </list-item>
          <list-item>
            <p>Severe, "thunderclap" headache</p>
          </list-item>
          <list-item>
            <p>Systemic illness signs such as fever</p>
          </list-item>
          <list-item>
            <p>Known illness which increases the risk for secondary headaches such as cancer or HIV</p>
          </list-item>
          <list-item>
            <p>Neurologic symptoms&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Headaches associated with Valsalva maneuvers<xref ref-type="bibr" rid="article-93576.r24">[24]</xref></p>
          </list-item>
        </list>
        <p>Physical exam findings concerning secondary headache causes include focal neurological deficits, papilledema, bitemporal hemianopia, homonymous hemianopia, decreased visual acuity, or increased pain with the Valsalva method.</p>
        <p>Primary chronic headaches often lack physical findings but may have autonomic&#x000a0;activation&#x000a0;or muscle tenderness in the occipital or cervical regions.</p>
      </sec>
      <sec id="article-93576.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Further evaluation may not be warranted in a straightforward chronic primary headache disorder. Still, many clinicians will advise baseline laboratory testing and brain imaging to exclude the secondary treatable causes.</p>
        <p>The necessary information that has to be gathered consists of these simple questions:</p>
        <list list-type="bullet">
          <list-item>
            <p>Demographic features of the patient: age, gender, race, profession</p>
          </list-item>
          <list-item>
            <p>When did the headache start?</p>
          </list-item>
          <list-item>
            <p>Where does it hurt? Location, irradiation.</p>
          </list-item>
          <list-item>
            <p>What is the intensity of the pain?</p>
          </list-item>
          <list-item>
            <p>How is the pain? Which are the qualitative characteristics of the pain?</p>
          </list-item>
          <list-item>
            <p>How long does the pain last?</p>
          </list-item>
          <list-item>
            <p>At which moment of the day does the pain appear?</p>
          </list-item>
          <list-item>
            <p>How has it evolved since it started?</p>
          </list-item>
          <list-item>
            <p>What is the frequency of appearance?</p>
          </list-item>
          <list-item>
            <p>What are the triggering situations?</p>
          </list-item>
          <list-item>
            <p>Simultaneous symptoms?</p>
          </list-item>
          <list-item>
            <p>Is it related to sleep?</p>
          </list-item>
          <list-item>
            <p>How does it get better or worse?</p>
          </list-item>
          <list-item>
            <p>Which medications do you take to make it better? What is the frequency of this medication?</p>
          </list-item>
        </list>
        <p>Laboratory workup includes&#x000a0;a complete blood count to look for infection. Erythrocyte sedimentation rate (ESR) is increased in giant cell arteritis and other vasculitides. A metabolic panel looks for metabolic causes of headaches and endocrine&#x000a0;testings to look for pituitary gland abnormalities.</p>
        <p>Magnetic resonance imaging (MRI) of the brain is the imaging modality of choice.<xref ref-type="bibr" rid="article-93576.r25">[25]</xref>&#x000a0;A&#x000a0;contrast study is often recommended to increase the sensitivity and specificity to detect structural abnormalities.&#x000a0;A need for vascular imaging&#x000a0;is based on the differential diagnosis. Further studies may be warranted depending upon the underlying cause. These may include positron emission tomography (PET) scan, magnetic resonance spectroscopy (MRS), and/or biopsy. A lumbar puncture may be required if there is suspicion of a CNS infection or&#x000a0;idiopathic intracranial hypertension.</p>
        <p><bold>Medication Overuse Headache by Drug Class</bold>&#x000a0;<bold>and Duration of Headache</bold></p>
        <list list-type="bullet">
          <list-item>
            <p>Ergotamine--&#x0003e; ten days/month for over three months</p>
          </list-item>
          <list-item>
            <p>Triptan--&#x0003e; ten days/month for over three months</p>
          </list-item>
          <list-item>
            <p>ASA--&#x0003e;15 days/month for over three months</p>
          </list-item>
          <list-item>
            <p>NSAIDs--&#x0003e;15 days/month for &#x0003e;3 months</p>
          </list-item>
          <list-item>
            <p>Acetaminophen/paracetamol--&#x0003e;15 days/month for over three months</p>
          </list-item>
          <list-item>
            <p>Opioids--&#x0003e; ten days/month for over three months</p>
          </list-item>
          <list-item>
            <p>Combination analgesics--&#x0003e; ten days/month for over three months</p>
          </list-item>
          <list-item>
            <p>Multiple drug classes--&#x0003e; ten days/month for over three months<xref ref-type="bibr" rid="article-93576.r22">[22]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-93576.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Treatment and management of chronic headache disorders depend upon the underlying etiology and may require an interprofessional approach.</p>
        <p>The patient should maintain a headache journal documenting their headache episodes and any accompanying triggers. If found, stressors should be avoided or minimized.&#x000a0;</p>
        <p>
<bold>Chronic Migraine</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Chronic migraine treatment should begin with setting the expectation that headache frequency and severity will decrease, but headaches will not be eliminated.</p>
          </list-item>
          <list-item>
            <p>The patient should be counseled that high caffeine intake, sleep deprivation, overuse of analgesics, and comorbid conditions can worsen chronic migraines.</p>
          </list-item>
          <list-item>
            <p>Prophylactic pharmacologic treatment should be used.&#x000a0;First-line therapy includes beta-blockers, anticonvulsants, and antidepressants. The most commonly used medications are propranolol, topiramate, and amitriptyline.<xref ref-type="bibr" rid="article-93576.r26">[26]</xref></p>
          </list-item>
          <list-item>
            <p>Botulinum toxin A is a Food and Drug Administration (FDA) approved treatment for chronic migraines and is considered second-line therapy.</p>
          </list-item>
          <list-item>
            <p>Monoclonal antibodies that target&#x000a0;calcitonin gene-related peptide (CGRP) are the newest development in chronic migraine treatment. Erenumab, fremanezumab, and galcanezumab are approved for chronic migraines, which have failed to respond to other treatments.<xref ref-type="bibr" rid="article-93576.r26">[26]</xref></p>
          </list-item>
          <list-item>
            <p>Triptans, steroids, NSAIDs, and opioids are often used to abort acute episodes, but routine use of these medications increases the risk of developing a medication-overuse headache.</p>
          </list-item>
          <list-item>
            <p>Patients may also benefit from psychological counseling if anxiety or depression is present.</p>
          </list-item>
          <list-item>
            <p>Manual medicine, such as spinal manipulation and trigger point treatment, may be used as complementary&#x000a0;or alternative therapy.<xref ref-type="bibr" rid="article-93576.r27">[27]</xref></p>
          </list-item>
          <list-item>
            <p>In drug-resistant cases, invasive procedures such as&#x000a0;sphenopalatine ganglion and occipital nerve blockades may be tried with variable results. Deep brain stimulation (DBS) is also used in some treatment-resistant cases.<xref ref-type="bibr" rid="article-93576.r28">[28]</xref><xref ref-type="bibr" rid="article-93576.r29">[29]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Chronic Tension Headache</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Amitriptyline, a tricyclic antidepressant, is recommended as the first-line treatment for chronic tension headaches.</p>
          </list-item>
          <list-item>
            <p>Amitriptyline, in addition to inhibiting serotonin and noradrenaline reuptake, also reduces tenderness in pericranial muscles.</p>
          </list-item>
          <list-item>
            <p>Tricyclic antidepressants increase the risk for cardiac arrhythmia, and patients should be screened for cardiovascular disorders before initiating therapy. In addition, patients over 40 should undergo an ECG.</p>
          </list-item>
          <list-item>
            <p>Anticonvulsants, such as topiramate and gabapentin, can be considered second-line treatment.</p>
          </list-item>
          <list-item>
            <p>Addressing the potential&#x000a0;musculoskeletal causes of tension headaches, treatment with physical therapy, acupuncture, trigger point injections, spinal manipulation,&#x000a0;or muscle relaxants may be beneficial.<xref ref-type="bibr" rid="article-93576.r30">[30]</xref></p>
          </list-item>
          <list-item>
            <p>Behavioral therapy, including cognitive-behavioral therapy, biofeedback, and relaxation techniques, is particularly helpful for patients with coexisting anxiety or depression.</p>
          </list-item>
        </list>
        <p>
<bold>Medication Overuse Headache</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Patient education about the potential for overuse of analgesic medication to lead to headache progression is key. Include the use of over-the-counter analgesics in the discussion.</p>
          </list-item>
          <list-item>
            <p>The physician initiates a preventative medication while simultaneously assisting the patient in discontinuing the causative drug.</p>
          </list-item>
          <list-item>
            <p>Patients may experience withdrawal symptoms of nausea&#x000a0;and anxiety for 2 to 10 days when the analgesic medication is discontinued.</p>
          </list-item>
          <list-item>
            <p>There is no consensus on the most appropriate medication for bridge therapy following discontinuation of the offending drug. Long-acting NSAIDs, prednisone, dihydroergotamine, and antiemetics are options.<xref ref-type="bibr" rid="article-93576.r31">[31]</xref>&#x000a0;The medication should not be from the same class as the offending medication.</p>
          </list-item>
          <list-item>
            <p>Medications that may be effective for prophylaxis include topiramate, amitryptiline, valproic acid, and beta-blockers. The choice of medication should be based upon comorbidities and the primary headache disorder.<xref ref-type="bibr" rid="article-93576.r32">[32]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Chronic Autonomic Cephalgia</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Indomethacin is the drug of choice for&#x000a0;paroxysmal hemicrania, hemicrania continua, primary stabbing headache, hypnic headache, and Valsalva-induced headaches (e.g., cough headache, exercise headache).</p>
          </list-item>
          <list-item>
            <p>Verapamil is the drug of choice for the prevention of chronic cluster headaches. However, Verapamil requires titration to become effective, and glucocorticoids or dihydroergotamine can be used for exacerbations.</p>
          </list-item>
          <list-item>
            <p>Chronic cluster headaches not responsive to pharmacologic therapy can be treated with a non-invasive vagus nerve stimulator or sphenopalatine ganglion microstimulator.<xref ref-type="bibr" rid="article-93576.r11">[11]</xref></p>
          </list-item>
          <list-item>
            <p>First-line prophylactic therapy for chronic SUNCT and SUNA is lamotrigine. Topiramate and gabapentin are alternatives.<xref ref-type="bibr" rid="article-93576.r33">[33]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-93576.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Medication-overuse headache&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Brain neoplasm&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Chronic infections (e.g., CNS tuberculosis)</p>
          </list-item>
          <list-item>
            <p>Chronic sinusitis</p>
          </list-item>
          <list-item>
            <p>Cervical spine-related pain</p>
          </list-item>
          <list-item>
            <p>CNS vasculitis</p>
          </list-item>
          <list-item>
            <p>Temporomandibular joint pathologies</p>
          </list-item>
          <list-item>
            <p>Idiopathic intracranial hypertension</p>
          </list-item>
          <list-item>
            <p>Chronic hydrocephalus</p>
          </list-item>
          <list-item>
            <p>Cerebral aneurysms</p>
          </list-item>
          <list-item>
            <p>Chronic paroxysmal hemicrania</p>
          </list-item>
          <list-item>
            <p>Dissection syndromes</p>
          </list-item>
          <list-item>
            <p>Encephalitis</p>
          </list-item>
          <list-item>
            <p>Subarachnoid/intracranial hemorrhage</p>
          </list-item>
          <list-item>
            <p>Meningitis</p>
          </list-item>
          <list-item>
            <p>Temporal/giant cell arteritis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-93576.s10" sec-type="Treatment Planning ">
        <title>Treatment Planning </title>
        <table-wrap id="article-93576.table0" position="float" orientation="portrait">
          <caption>
            <title>Table 1. Acute therapy for migraine&#x000a0;*Adverse effects in this section pertain to all triptans unless specified</title>
          </caption>
          <table style="height: 1318px; width: 1117px;" border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr style="height: 15px;">
                <td style="width: 236px; height: 15px;" rowspan="1" colspan="1">
<bold>Drug class/Drug</bold>
</td>
                <td style="width: 236.0625px; height: 15px;" rowspan="1" colspan="1">
<bold>Drug</bold>
</td>
                <td style="width: 234.9375px; height: 15px;" rowspan="1" colspan="1">
<bold>Dose range</bold>
</td>
                <td style="width: 236px; height: 15px;" rowspan="1" colspan="1">
<bold>Notes</bold>
</td>
              </tr>
              <tr style="height: 142px;">
                <td style="width: 236px; height: 142px;" rowspan="1" colspan="1">Nonsteroidal anti-inflammatory drugs</td>
                <td style="width: 236.0625px; height: 142px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Aspirin<xref ref-type="bibr" rid="article-93576.r34">[34]</xref></p></list-item><list-item><p>Ibuprofen</p></list-item><list-item><p>Naproxen</p></list-item><list-item><p>Diclofenac</p></list-item><list-item><p>Diclofenac epolamine</p></list-item><list-item><p>Tolfemanic acid</p></list-item><list-item><p>Celecoxib<xref ref-type="bibr" rid="article-93576.r35">[35]</xref></p></list-item><list-item><p>Dexletoprofen</p></list-item></list>
</td>
                <td style="width: 234.9375px; height: 142px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>900-100 mg</p></list-item><list-item><p>400-600 mg</p></list-item><list-item><p>275-825 mg</p></list-item><list-item><p>50-100 mg</p></list-item><list-item><p>65 mg</p></list-item><list-item><p>200 mg</p></list-item><list-item><p>120&#x000a0;mg</p></list-item><list-item><p>50 mg</p></list-item></list>
</td>
                <td style="width: 236px; height: 142px;" rowspan="1" colspan="1">All NSAIDs have similar efficacy&#x000a0;</td>
              </tr>
              <tr style="height: 37px;">
                <td style="width: 236px; height: 37px;" rowspan="1" colspan="1">Non-opioid analgesic</td>
                <td style="width: 236.0625px; height: 37px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Acetaminophen<xref ref-type="bibr" rid="article-93576.r36">[36]</xref></p></list-item></list>
</td>
                <td style="width: 234.9375px; height: 37px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>1000-3000 g</p></list-item></list>
</td>
                <td style="width: 236px; height: 37px;" rowspan="1" colspan="1">Acute-life threatening hepatotoxicity at &#x0003e; 4 g/d</td>
              </tr>
              <tr style="height: 586px;">
                <td style="width: 236px; height: 586px;" rowspan="1" colspan="1">
<p>Serotonin 1b/1d agonists (triptans)</p>
<p>(Sumatriptan)*<xref ref-type="bibr" rid="article-93576.r37">[37]</xref></p>
</td>
                <td style="width: 236.0625px; height: 586px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Sumatriptan (oral)</p></list-item></list>
<list list-type="bullet"><list-item><p>Sumatriptan (intranasal solution)<xref ref-type="bibr" rid="article-93576.r38">[38]</xref></p></list-item></list>
<list list-type="bullet"><list-item><p>Sumatriptan (intranasal powder)</p></list-item></list>
<list list-type="bullet"><list-item><p>Sumatriptan (spray)</p></list-item></list>
<list list-type="bullet"><list-item><p>Sumatriptan (subcutaneous)</p></list-item></list>
</td>
                <td style="width: 234.9375px; height: 586px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>50-100&#x000a0;mg as a single dose, maximum dose: 200 mg/d</p></list-item></list>
<list list-type="bullet"><list-item><p>20 mg as a single dose in 1 nostril; if symptoms persist, may repeat dose after &#x02265;2 hours, maximum dose: 40 mg/d</p></list-item></list>
<list list-type="bullet"><list-item><p>22 mg as a single dose, may repeat dose after &#x02265;2 hours if symptoms persist or return, maximum dose: 44 mg/d</p></list-item></list>
<list list-type="bullet"><list-item><p>10 mg as a single dose in 1 nostril. Repeat dose after &#x02265;1 hour if symptoms persist or return; maximum dose: 30 mg/d</p></list-item></list>
<list list-type="bullet"><list-item><p>6 mg as a single dose, may repeat dose (usually same as the first dose) after &#x02265;1 hour if symptoms persist or return, or lesser dosage if 6 mg was not tolerated, maximum dose: 6 mg/dose; 12 mg/d</p></list-item></list>
</td>
                <td style="width: 236px; height: 586px;" rowspan="1" colspan="1">
<p>All formulations of triptans are <bold>contraindicated</bold> in <bold>severe hepatic impairment.</bold></p>
<p>Contraindicated in patients with cardiovascular illness as <bold>prolonged QT interval on ECG</bold> and subsequent ventricular arrhythmias, including <bold>torsades de pointes</bold> (TdP) and <bold>ventricular fibrillation,</bold>&#x000a0;are reported.</p>
<p>It may also cause&#x000a0;<bold>dizziness, lethargy, tremor, vertigo, akathisia, dystonia,</bold> and pathological laughter.</p>
<p>Other vasospasm-related events include <bold>peripheral ischemia, ischemic colitis, splenic infarction,&#x000a0;</bold>and <bold>Raynaud disease.</bold></p>
<p>It should be avoided in patients with&#x000a0;<bold>uncontrolled hypertension&#x000a0;</bold>and&#x000a0;<bold>pregnancy.</bold></p>
<p>There are ocular side effects like transient and permanent <bold>blindness</bold> and significant partial <bold>vision loss.</bold></p>
<p>The use of concomitant serotonergic drugs may cause&#x000a0;<bold>serotonin syndrome.</bold></p>
<p><bold>Unpleasant taste</bold> is lower with intranasal zolmitriptan as compared to intranasal sumatriptan.</p>
<p>Patients who do not respond to one triptan may respond to another.</p>
<p>Naratriptan and frovatriptan have a slower&#x000a0;onset and lower efficacy.</p>
</td>
              </tr>
              <tr style="height: 108px;">
                <td style="width: 236px; height: 108px;" rowspan="1" colspan="1">
<p>Serotonin 1b/1d agonists (triptans)</p>
<p>(Naratriptan)&#x000a0;</p>
</td>
                <td style="width: 236.0625px; height: 108px;" rowspan="1" colspan="1">&#x000a0;
<list list-type="bullet"><list-item><p>Naratriptan<xref ref-type="bibr" rid="article-93576.r39">[39]</xref></p></list-item></list>
</td>
                <td style="width: 234.9375px; height: 108px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>2.5 mg as a single dose; may repeat dose after &#x02265;4 hours; maximum dose: 2.5 mg/dose; 5 mg/d.</p></list-item></list>
</td>
                <td style="width: 236px; height: 108px;" rowspan="1" colspan="1">
<p>Use within 24 hours of an ergotamine preparation or a different triptan is <bold>not advised</bold>.</p>
<p>Contraindicated with<bold> severe renal impairment</bold> (CrCl &#x0003c;15 mL/minute).</p>
</td>
              </tr>
              <tr style="height: 164px;">
                <td style="width: 236px; height: 164px;" rowspan="1" colspan="1">
<p>Serotonin 1b/1d agonists (triptans)</p>
<p>(Zolmitriptan)</p>
</td>
                <td style="width: 236.0625px; height: 164px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Zolmitriptan (oral)</p></list-item></list>
<list list-type="bullet"><list-item><p>Zolmitriptan (intranasal)</p></list-item></list>
</td>
                <td style="width: 234.9375px; height: 164px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>&#x000a0;2.5 mg as a single dose; may repeat dose after &#x02265;2 hours; maximum dose: 5 mg/dose; 10 mg/d<xref ref-type="bibr" rid="article-93576.r40">[40]</xref></p></list-item></list>
<list list-type="bullet"><list-item><p>2.5 to 5 mg as a single dose; may repeat dose after &#x02265;2 hours; maximum: 5 mg/dose; 10 mg/d</p></list-item></list>
</td>
                <td style="width: 236px; height: 164px;" rowspan="1" colspan="1">Refer to the section on sumatriptan above for the side effects of triptans.</td>
              </tr>
              <tr style="height: 82px;">
                <td style="width: 236px; height: 82px;" rowspan="1" colspan="1">
<p>Serotonin 1b/1d agonists (triptans)</p>
<p>(Frovatriptan)</p>
</td>
                <td style="width: 236.0625px; height: 82px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Frovatriptan</p></list-item></list>
</td>
                <td style="width: 234.9375px; height: 82px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>2.5 mg as a single dose; may repeat dose after &#x02265;2 hours if needed; maximum dose: 2.5 mg/dose; 5 mg/d &#x000a0;</p></list-item></list>
</td>
                <td style="width: 236px; height: 82px;" rowspan="1" colspan="1">Slower onset&#x000a0;</td>
              </tr>
              <tr style="height: 15px;">
                <td style="width: 236px; height: 15px;" rowspan="1" colspan="1">
<p>Serotonin 1b/1d agonists (triptans)</p>
<p>(Almotriptan)&#x000a0;</p>
</td>
                <td style="width: 236.0625px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Almotriptan&#x000a0;</p></list-item></list>
</td>
                <td style="width: 234.9375px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>12.5 mg as a single dose; may repeat dose after &#x02265;2 hours when needed; maximum dose: 12.5 mg/dose; 25 mg/d<xref ref-type="bibr" rid="article-93576.r41">[41]</xref></p></list-item></list>
</td>
                <td style="width: 236px; height: 15px;" rowspan="1" colspan="1">Reduce dose to half with <bold>hepatic impairment&#x000a0;</bold></td>
              </tr>
              <tr style="height: 15px;">
                <td style="width: 236px; height: 15px;" rowspan="1" colspan="1">
<p>Serotonin 1b/1d agonists (triptans)</p>
<p>(Rizatriptan)</p>
</td>
                <td style="width: 236.0625px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Rizatriptan</p></list-item></list>
</td>
                <td style="width: 234.9375px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>5 to 10 mg as a single dose; may repeat dose after &#x02265;2 hours if needed; maximum dose: 20-30 mg/d</p></list-item></list>
</td>
                <td style="width: 236px; height: 15px;" rowspan="1" colspan="1"><bold>Propranolol</bold> increases rizatriptan levels by 70%. So the dose of rizatriptan&#x000a0;must be adjusted downward in these patients.</td>
              </tr>
              <tr style="height: 15px;">
                <td style="width: 236px; height: 15px;" rowspan="1" colspan="1">
<p>Serotonin 1b/1d agonists (triptans)</p>
<p>(Eletriptan)</p>
</td>
                <td style="width: 236.0625px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Eletriptan<xref ref-type="bibr" rid="article-93576.r42">[42]</xref></p></list-item></list>
</td>
                <td style="width: 234.9375px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>40 mg as a single dose; may repeat dose after &#x02265;2 hours if needed; maximum dose: 40 mg/dose; 80 mg/d</p></list-item></list>
</td>
                <td style="width: 236px; height: 15px;" rowspan="1" colspan="1">Primarily metabolized by cytochrome P-450 enzyme CYP3A4. Not advised within at least 72 hours of treatment with other drugs that are <bold>potent CYP3A4 inhibitors:</bold> itraconazole, ketoconazole, clarithromycin, nefazodone,&#x000a0;troleandomycin, ritonavir, and nelfinavir.</td>
              </tr>
              <tr style="height: 15px;">
                <td style="width: 236px; height: 15px;" rowspan="1" colspan="1">
<p>&#x000a0;Antiemetics</p>
</td>
                <td style="width: 236.0625px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Metoclopramide (IV, IM, oral)<xref ref-type="bibr" rid="article-93576.r43">[43]</xref></p></list-item></list>
<list list-type="bullet"><list-item><p>Prochlorperazine (IV, IM)</p></list-item></list>
</td>
                <td style="width: 234.9375px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>10-20 mg as a single dose</p></list-item></list>
<list list-type="bullet"><list-item><p>10 mg as a single dose</p></list-item></list>
</td>
                <td style="width: 236px; height: 15px;" rowspan="1" colspan="1">IV route is preferred for metoclopramide. Pretreat with diphenhydramine to prevent <bold>akathisia</bold> and other <bold>acute dystonic reactions.</bold></td>
              </tr>
              <tr style="height: 15px;">
                <td style="width: 236px; height: 15px;" rowspan="1" colspan="1">Calcitonin-gene-related peptide (CGRP) antagonists</td>
                <td style="width: 236.0625px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Rimegepant<xref ref-type="bibr" rid="article-93576.r44">[44]</xref></p></list-item></list>
<list list-type="bullet"><list-item><p>Ubrogepant<xref ref-type="bibr" rid="article-93576.r45">[45]</xref></p></list-item></list>
</td>
                <td style="width: 234.9375px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>75 mg every other day; maximum dose: 75 mg/d</p></list-item></list>
<list list-type="bullet"><list-item><p>50 to 100 mg as a single dose; may repeat dose after &#x02265;2 hours if needed; maximum dose: 200 mg/d</p></list-item></list>
</td>
                <td style="width: 236px; height: 15px;" rowspan="1" colspan="1">
<p>Administration early in the course of a migraine attack may improve response to treatment.</p>
<p>Second-line therapy when triptans are contraindicated, poorly tolerated, or ineffective.</p>
<p>More studies are needed to establish efficacy and safety.</p>
</td>
              </tr>
              <tr style="height: 15px;">
                <td style="width: 236px; height: 15px;" rowspan="1" colspan="1">&#x000a0;Serotonin 5-HT1F receptor agonist</td>
                <td style="width: 236.0625px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Lasmiditan<xref ref-type="bibr" rid="article-93576.r46">[46]</xref></p></list-item></list>
</td>
                <td style="width: 234.9375px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>50 to 100 mg as a single dose; may increase to 100 or 200 mg as a single dose if needed; repeat doses have not established efficacy.</p></list-item></list>
</td>
                <td style="width: 236px; height: 15px;" rowspan="1" colspan="1">
<p>Administration early in the course of a migraine attack may improve response to treatment.</p>
<p>Second-line therapy when triptans are contraindicated, poorly tolerated, or ineffective.</p>
<p>A major side effect is dizziness (9% to 17%). Wait for at least 8 hours between dosing and driving or operating heavy machinery.</p>
<p>May enhance the CNS depressant effect of alcohol.</p>
</td>
              </tr>
              <tr style="height: 15px;">
                <td style="width: 236px; height: 15px;" rowspan="1" colspan="1">&#x000a0;Ergot derivative</td>
                <td style="width: 236.0625px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>&#x000a0;Dihydroergotamine<xref ref-type="bibr" rid="article-93576.r47">[47]</xref></p></list-item></list>
</td>
                <td style="width: 234.9375px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>IM:&#x000a0;1 mg as a single dose; may repeat hourly as required; maximum dose: 3 mg/d, 6 mg/week</p></list-item><list-item><p>IV:&#x000a0;1 mg as a single dose; may repeat hourly as required; maximum dose: 2 mg/d, 6 mg/week</p></list-item><list-item><p>SUBQUT: 1 mg as a single dose; may repeat&#x000a0;every 2 hours as required; maximum dose: 3 mg/d, 6 mg/week</p></list-item><list-item><p>Intranasal :&#x000a0;0.5 mg per spray: 1 spray (0.5 mg) into each nostril; repeat after 15 minutes (total of 4 sprays per dose); maximum dose: 4 sprays (1 dose)/d</p></list-item></list>
</td>
                <td style="width: 236px; height: 15px;" rowspan="1" colspan="1">
<p>Use is contraindicated in severe hepatic or renal impairment as well as pregnancy or breastfeeding.</p>
<p>Also contraindicated in patients with hypertension or ischemic heart disease.</p>
<p>Should not be used within 24 hours of triptans or ergot-like agents.</p>
<p>Use&#x000a0;with potent inhibitors of CYP3A4 (including azole antifungals, protease inhibitors, and some macrolide antibiotics) is also avoided.</p>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <table-wrap id="article-93576.table1" position="float" orientation="portrait">
          <caption>
            <title>Table 2. Preventive therapy for migraine[48]</title>
          </caption>
          <table style="height: 631px; width: 902.53125px;" border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr style="height: 15px;">
                <td style="width: 158px; height: 15px;" rowspan="1" colspan="1">
<bold>Drug Class</bold>
</td>
                <td style="width: 179px; height: 15px;" rowspan="1" colspan="1">
<bold>Drug</bold>
</td>
                <td style="width: 173px; height: 15px;" rowspan="1" colspan="1">
<bold>Dose Range</bold>
</td>
                <td style="width: 217.53125px; height: 15px;" rowspan="1" colspan="1">
<bold>Adverse Effects/Contraindications</bold>
</td>
              </tr>
              <tr style="height: 67px;">
                <td style="width: 158px; height: 67px;" rowspan="1" colspan="1">Beta-adrenoceptor blockers<xref ref-type="bibr" rid="article-93576.r49">[49]</xref></td>
                <td style="width: 179px; height: 67px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Propranolol</p></list-item><list-item><p>Metoprolol</p></list-item><list-item><p>Timolol</p></list-item></list>
</td>
                <td style="width: 173px; height: 67px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>80-240 mg</p></list-item><list-item><p>50-150 mg</p></list-item><list-item><p>10-20 mg</p></list-item></list>
</td>
                <td style="width: 217.53125px; height: 67px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Contraindicated in asthma, syncope, heart block</p></list-item></list>
</td>
              </tr>
              <tr style="height: 67px;">
                <td style="width: 158px; height: 67px;" rowspan="1" colspan="1">Antidepressants</td>
                <td style="width: 179px; height: 67px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Amitriptyline</p></list-item><list-item><p>Nortriptyline</p></list-item><list-item><p>Venlafaxine</p></list-item></list>
</td>
                <td style="width: 173px; height: 67px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>10-150 mg</p></list-item><list-item><p>25-100 mg</p></list-item><list-item><p>37.5-150 mg</p></list-item></list>
</td>
                <td style="width: 217.53125px; height: 67px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Somnolence</p></list-item><list-item><p>Insomnia, hypertension</p></list-item></list>
</td>
              </tr>
              <tr style="height: 37px;">
                <td style="width: 158px; height: 37px;" rowspan="1" colspan="1">Calcium-channel blockers</td>
                <td style="width: 179px; height: 37px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Verapamil<xref ref-type="bibr" rid="article-93576.r50">[50]</xref></p></list-item></list>
</td>
                <td style="width: 173px; height: 37px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>180-480 mg</p></list-item></list>
</td>
                <td style="width: 217.53125px; height: 37px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Constipation, hypotension, edema</p></list-item></list>
</td>
              </tr>
              <tr style="height: 97px;">
                <td style="width: 158px; height: 97px;" rowspan="1" colspan="1">Antiepileptic drugs<xref ref-type="bibr" rid="article-93576.r49">[49]</xref></td>
                <td style="width: 179px; height: 97px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Divalproex sodium</p></list-item><list-item><p>Topiramate</p></list-item><list-item><p>Gabapentin</p></list-item></list>
</td>
                <td style="width: 173px; height: 97px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>200-1500 mg</p></list-item><list-item><p>25-150 mg</p></list-item><list-item><p>300-1800 mg</p></list-item></list>
</td>
                <td style="width: 217.53125px; height: 97px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Weight gain, thrombocytopenia, tremor</p></list-item><list-item><p>Renal calculi, amnesia, glaucoma, dysequilibrium, weight loss</p></list-item></list>
</td>
              </tr>
              <tr style="height: 97px;">
                <td style="width: 158px; height: 97px;" rowspan="1" colspan="1">CGRP monoclonal antibodies</td>
                <td style="width: 179px; height: 97px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Erenumab</p></list-item><list-item><p>Galcanezumab</p></list-item></list>
</td>
                <td style="width: 173px; height: 97px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>70&#x000a0;to 140 mg every four weeks, subcutaneously</p></list-item><list-item><p>120 mg monthly subcut</p></list-item></list>
</td>
                <td style="width: 217.53125px; height: 97px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Injection site reactions, muscle spasm, hypersensitivity reaction</p></list-item><list-item><p>Injection site reactions, vertigo, pruritus, constipation</p></list-item></list>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="article-93576.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis of chronic headaches is variable. Anxiety and mood disorders, elevated stress levels, insufficient sleep, poor headache management, and low socioeconomic status are the primary prognostic characteristics&#x02014;patients with higher expectations for treatment display a better prognosis for decreased headache intensity and frequency. No specific age group has an improved response to treatment. Incidence at an older age generally correlates to less severe symptoms. Employed patients responded better to treatment than those patients on medical leave.<xref ref-type="bibr" rid="article-93576.r9">[9]</xref>&#x000a0;Exercise, prophylactic medication regimen compliance, and cessation of overused medications tend to&#x000a0;lead to a favorable prognosis.<xref ref-type="bibr" rid="article-93576.r1">[1]</xref></p>
      </sec>
      <sec id="article-93576.s12" sec-type="Complications">
        <title>Complications</title>
        <list list-type="bullet">
          <list-item>
            <p>Mood disorders</p>
          </list-item>
          <list-item>
            <p>Decreased quality of life</p>
          </list-item>
          <list-item>
            <p>Suicide</p>
          </list-item>
          <list-item>
            <p>Unemployment</p>
          </list-item>
          <list-item>
            <p>Progressive neurological deficits</p>
          </list-item>
          <list-item>
            <p>Vision loss</p>
          </list-item>
          <list-item>
            <p>Seizures</p>
          </list-item>
          <list-item>
            <p>Drowsiness</p>
          </list-item>
          <list-item>
            <p>Medication adverse effects</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-93576.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients should be educated to become more aware of their headache symptoms and triggers. Interventions should be clearly explained to patients.&#x000a0;&#x000a0;</p>
        <p>The role of over-the-counter analgesics in medication overuse headaches must be explained to patients. Patients with all types of primary headaches have the potential to overuse analgesics. They should be counseled on the potential for frequent use of these medications to worsen the intensity and frequency of headaches.</p>
      </sec>
      <sec id="article-93576.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Management of patients with chronic headaches will require the efforts of an interprofessional healthcare team. The interprofessional care provided to the patient must use an integrated care pathway combined with an evidence-based approach to planning and evaluating all joint activities. Primary care clinicians (MDs, DOs, NPs, and PAs) obtain the assistance of&#x000a0;an internist, a neurologist, or a headache specialist if there's any doubt about the diagnosis. Nurses and psychologists can assist team management by teaching lifestyle changes, mental health supervision, drug overuse detoxification, and medication use recommendations.</p>
        <p>Pharmacists can aid the team in checking for appropriate dosing and determining drug interactions, especially if the patient is treated for chronic migraines. Nursing must coordinate activities between the various disciplines and often serve as initial contact points for patients and other team members. All interprofessional team members must document any changes in patient status as they observe them and notify the appropriate other parties on the healthcare team so additional diagnostic and/or therapeutic measures can occur if necessary. Open communication among team members is crucial to optimal patient care.</p>
        <p>An interprofessional team that provides an integrated approach to patient care can help achieve the best possible outcomes. Collaboration, shared decision-making, and communication&#x000a0;are&#x000a0;crucial for a good result. [Level 5]</p>
      </sec>
      <sec id="article-93576.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=93576&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=93576">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/neurology/chronic-headaches/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=93576">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/93576/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=93576">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-93576.s16">
        <title>References</title>
        <ref id="article-93576.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murinova</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Krashin</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Chronic daily headache.</article-title>
            <source>Phys Med Rehabil Clin N Am</source>
            <year>2015</year>
            <month>May</month>
            <volume>26</volume>
            <issue>2</issue>
            <fpage>375</fpage>
            <page-range>375-89</page-range>
            <pub-id pub-id-type="pmid">25952071</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93576.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sheeler</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Garza</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Vargas</surname>
                <given-names>BB</given-names>
              </name>
              <name>
                <surname>O'Neil</surname>
                <given-names>AE</given-names>
              </name>
            </person-group>
            <article-title>Chronic Daily Headache: Ten Steps for Primary Care Providers to Regain Control.</article-title>
            <source>Headache</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>56</volume>
            <issue>10</issue>
            <fpage>1675</fpage>
            <page-range>1675-1684</page-range>
            <pub-id pub-id-type="pmid">27552176</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93576.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yancey</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Sheridan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Koren</surname>
                <given-names>KG</given-names>
              </name>
            </person-group>
            <article-title>Chronic daily headache: diagnosis and management.</article-title>
            <source>Am Fam Physician</source>
            <year>2014</year>
            <month>Apr</month>
            <day>15</day>
            <volume>89</volume>
            <issue>8</issue>
            <fpage>642</fpage>
            <page-range>642-8</page-range>
            <pub-id pub-id-type="pmid">24784123</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93576.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <article-title>Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition.</article-title>
            <source>Cephalalgia</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>38</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-211</page-range>
            <pub-id pub-id-type="pmid">29368949</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93576.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>&#x000d6;zge</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Faedda</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Abu-Arafeh</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Gelfand</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Goadsby</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Cuvellier</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Valeriani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sergeev</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Barlow</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ulud&#x000fc;z</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Yal&#x00131;n</surname>
                <given-names>O&#x000d6;</given-names>
              </name>
              <name>
                <surname>Lipton</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Rapoport</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Guidetti</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Experts' opinion about the primary headache diagnostic criteria of the ICHD-3rd edition beta in children and adolescents.</article-title>
            <source>J Headache Pain</source>
            <year>2017</year>
            <month>Nov</month>
            <day>23</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>109</fpage>
            <pub-id pub-id-type="pmid">29285570</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93576.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yamani</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Olesen</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>New daily persistent headache: a systematic review on an enigmatic disorder.</article-title>
            <source>J Headache Pain</source>
            <year>2019</year>
            <month>Jul</month>
            <day>15</day>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>80</fpage>
            <pub-id pub-id-type="pmid">31307396</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93576.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vandenbussche</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Laterza</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lisicki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lloyd</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lupi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tischler</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Toom</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Vandervorst</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Quintana</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Paemeleire</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Katsarava</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Medication-overuse headache: a widely recognized entity amidst ongoing debate.</article-title>
            <source>J Headache Pain</source>
            <year>2018</year>
            <month>Jul</month>
            <day>13</day>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>50</fpage>
            <pub-id pub-id-type="pmid">30003412</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93576.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stovner</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Al Jumah</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Birbeck</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Gururaj</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Katsarava</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Queiroz</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Scher</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Tekle-Haimanot</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Steiner</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>The methodology of population surveys of headache prevalence, burden and cost: principles and recommendations from the Global Campaign against Headache.</article-title>
            <source>J Headache Pain</source>
            <year>2014</year>
            <month>Jan</month>
            <day>27</day>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>5</fpage>
            <pub-id pub-id-type="pmid">24467862</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93576.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Probyn</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bowers</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Caldwell</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mistry</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Underwood</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Matharu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pincus</surname>
                <given-names>T</given-names>
              </name>
              <collab>CHESS Team</collab>
            </person-group>
            <article-title>Prognostic factors for chronic headache: A systematic review.</article-title>
            <source>Neurology</source>
            <year>2017</year>
            <month>Jul</month>
            <day>18</day>
            <volume>89</volume>
            <issue>3</issue>
            <fpage>291</fpage>
            <page-range>291-301</page-range>
            <pub-id pub-id-type="pmid">28615422</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93576.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Diener</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Solbach</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Holle</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gaul</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Integrated care for chronic migraine patients: epidemiology, burden, diagnosis and treatment options.</article-title>
            <source>Clin Med (Lond)</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>15</volume>
            <issue>4</issue>
            <fpage>344</fpage>
            <page-range>344-50</page-range>
            <pub-id pub-id-type="pmid">26407383</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93576.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wei</surname>
                <given-names>DY</given-names>
              </name>
              <name>
                <surname>Khalil</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Goadsby</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Managing cluster headache.</article-title>
            <source>Pract Neurol</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>19</volume>
            <issue>6</issue>
            <fpage>521</fpage>
            <page-range>521-528</page-range>
            <pub-id pub-id-type="pmid">31278205</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93576.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Su</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Chronic migraine: A process of dysmodulation and sensitization.</article-title>
            <source>Mol Pain</source>
            <year>2018</year>
            <season>Jan-Dec</season>
            <volume>14</volume>
            <fpage>1744806918767697</fpage>
            <pub-id pub-id-type="pmid">29642749</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93576.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Deen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Christensen</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Hougaard</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Knudsen</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Ashina</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Serotonergic mechanisms in the migraine brain - a systematic review.</article-title>
            <source>Cephalalgia</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>37</volume>
            <issue>3</issue>
            <fpage>251</fpage>
            <page-range>251-264</page-range>
            <pub-id pub-id-type="pmid">27013238</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93576.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Deen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Hougaard</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>N&#x000f8;rgaard</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Eiberg</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lehel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ashina</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Knudsen</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>High brain serotonin levels in migraine between attacks: A 5-HT<sub>4</sub> receptor binding PET study.</article-title>
            <source>Neuroimage Clin</source>
            <year>2018</year>
            <volume>18</volume>
            <fpage>97</fpage>
            <page-range>97-102</page-range>
            <pub-id pub-id-type="pmid">29387527</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93576.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iyengar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Ossipov</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Aurora</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>CGRP and the Trigeminal System in Migraine.</article-title>
            <source>Headache</source>
            <year>2019</year>
            <month>May</month>
            <volume>59</volume>
            <issue>5</issue>
            <fpage>659</fpage>
            <page-range>659-681</page-range>
            <pub-id pub-id-type="pmid">30982963</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93576.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Edvinsson</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Role of CGRP in Migraine.</article-title>
            <source>Handb Exp Pharmacol</source>
            <year>2019</year>
            <volume>255</volume>
            <fpage>121</fpage>
            <page-range>121-130</page-range>
            <pub-id pub-id-type="pmid">30725283</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93576.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schwedt</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Chong</surname>
                <given-names>CD</given-names>
              </name>
            </person-group>
            <article-title>Medication Overuse Headache: Pathophysiological Insights from Structural and Functional Brain MRI Research.</article-title>
            <source>Headache</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>57</volume>
            <issue>7</issue>
            <fpage>1173</fpage>
            <page-range>1173-1178</page-range>
            <pub-id pub-id-type="pmid">28160280</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93576.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lai</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Neuroimaging Findings in Patients with Medication Overuse Headache.</article-title>
            <source>Curr Pain Headache Rep</source>
            <year>2018</year>
            <month>Jan</month>
            <day>16</day>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <pub-id pub-id-type="pmid">29340793</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93576.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Srikiatkhachorn</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tarasub</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Govitrapong</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Effect of chronic analgesic exposure on the central serotonin system: a possible mechanism of analgesic abuse headache.</article-title>
            <source>Headache</source>
            <year>2000</year>
            <month>May</month>
            <volume>40</volume>
            <issue>5</issue>
            <fpage>343</fpage>
            <page-range>343-50</page-range>
            <pub-id pub-id-type="pmid">10849027</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93576.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Di Lorenzo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Coppola</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Curr&#x000e0;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Grieco</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Santorelli</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Lepre</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Porretta</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pascale</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pierelli</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Cortical response to somatosensory stimulation in medication overuse headache patients is influenced by angiotensin converting enzyme (ACE) I/D genetic polymorphism.</article-title>
            <source>Cephalalgia</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>32</volume>
            <issue>16</issue>
            <fpage>1189</fpage>
            <page-range>1189-97</page-range>
            <pub-id pub-id-type="pmid">23053304</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93576.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wei</surname>
                <given-names>DY</given-names>
              </name>
              <name>
                <surname>Yuan Ong</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Goadsby</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Cluster Headache: Epidemiology, Pathophysiology, Clinical Features, and Diagnosis.</article-title>
            <source>Ann Indian Acad Neurol</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>21</volume>
            <issue>Suppl 1</issue>
            <fpage>S3</fpage>
            <page-range>S3-S8</page-range>
            <pub-id pub-id-type="pmid">29720812</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93576.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <collab>Headache Classification Committee of the International Headache Society (IHS)</collab>
            <article-title>The International Classification of Headache Disorders, 3rd edition (beta version).</article-title>
            <source>Cephalalgia</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>33</volume>
            <issue>9</issue>
            <fpage>629</fpage>
            <page-range>629-808</page-range>
            <pub-id pub-id-type="pmid">23771276</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93576.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Micieli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Robblee</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Medication-overuse headache.</article-title>
            <source>CMAJ</source>
            <year>2018</year>
            <month>Mar</month>
            <day>12</day>
            <volume>190</volume>
            <issue>10</issue>
            <fpage>E296</fpage>
            <pub-id pub-id-type="pmid">29530871</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93576.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>VME</given-names>
              </name>
              <name>
                <surname>Ang</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Soon</surname>
                <given-names>DTL</given-names>
              </name>
              <name>
                <surname>Ong</surname>
                <given-names>JJY</given-names>
              </name>
              <name>
                <surname>Loh</surname>
                <given-names>VWK</given-names>
              </name>
            </person-group>
            <article-title>The adult patient with headache.</article-title>
            <source>Singapore Med J</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>59</volume>
            <issue>8</issue>
            <fpage>399</fpage>
            <page-range>399-406</page-range>
            <pub-id pub-id-type="pmid">30175370</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93576.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Loder</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Weizenbaum</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Frishberg</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Silberstein</surname>
                <given-names>S</given-names>
              </name>
              <collab>American Headache Society Choosing Wisely Task Force</collab>
            </person-group>
            <article-title>Choosing wisely in headache medicine: the American Headache Society's list of five things physicians and patients should question.</article-title>
            <source>Headache</source>
            <year>2013</year>
            <season>Nov-Dec</season>
            <volume>53</volume>
            <issue>10</issue>
            <fpage>1651</fpage>
            <page-range>1651-9</page-range>
            <pub-id pub-id-type="pmid">24266337</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93576.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Agostoni</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Barbanti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Calabresi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Colombo</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Cortelli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Frediani</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Geppetti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Grazzi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Leone</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Martelletti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pini</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Prudenzano</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Sarchielli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tedeschi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Russo</surname>
                <given-names>A</given-names>
              </name>
              <collab>Italian chronic migraine group</collab>
            </person-group>
            <article-title>Current and emerging evidence-based treatment options in chronic migraine: a narrative review.</article-title>
            <source>J Headache Pain</source>
            <year>2019</year>
            <month>Aug</month>
            <day>30</day>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>92</fpage>
            <pub-id pub-id-type="pmid">31470791</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93576.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Whalen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yao</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Leder</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>A Short Review of the Treatment of Headaches Using Osteopathic Manipulative Treatment.</article-title>
            <source>Curr Pain Headache Rep</source>
            <year>2018</year>
            <month>Oct</month>
            <day>05</day>
            <volume>22</volume>
            <issue>12</issue>
            <fpage>82</fpage>
            <pub-id pub-id-type="pmid">30291550</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93576.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vyas</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Dadey</surname>
                <given-names>DY</given-names>
              </name>
              <name>
                <surname>Pendharkar</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Sussman</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Cowan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Halpern</surname>
                <given-names>CH</given-names>
              </name>
            </person-group>
            <article-title>Deep Brain Stimulation for Chronic Cluster Headache: A Review.</article-title>
            <source>Neuromodulation</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>22</volume>
            <issue>4</issue>
            <fpage>388</fpage>
            <page-range>388-397</page-range>
            <pub-id pub-id-type="pmid">30303584</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93576.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leone</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Deep brain stimulation in headache.</article-title>
            <source>Lancet Neurol</source>
            <year>2006</year>
            <month>Oct</month>
            <volume>5</volume>
            <issue>10</issue>
            <fpage>873</fpage>
            <page-range>873-7</page-range>
            <pub-id pub-id-type="pmid">16987734</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93576.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Linde</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Allais</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Brinkhaus</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Manheimer</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Vickers</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>Acupuncture for tension-type headache.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2009</year>
            <month>Jan</month>
            <day>21</day>
            <issue>1</issue>
            <fpage>CD007587</fpage>
            <pub-id pub-id-type="pmid">19160338</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93576.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boes</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Black</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Dodick</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>Pathophysiology and management of transformed migraine and medication overuse headache.</article-title>
            <source>Semin Neurol</source>
            <year>2006</year>
            <month>Apr</month>
            <volume>26</volume>
            <issue>2</issue>
            <fpage>232</fpage>
            <page-range>232-41</page-range>
            <pub-id pub-id-type="pmid">16628534</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93576.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tassorelli</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Allena</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>De Icco</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sances</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Katsarava</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Lainez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Leston</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fadic</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Spadafora</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pagani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nappi</surname>
                <given-names>G</given-names>
              </name>
              <collab>the COMOESTAS Consortium</collab>
            </person-group>
            <article-title>A consensus protocol for the management of medication-overuse headache: Evaluation in a multicentric, multinational study.</article-title>
            <source>Cephalalgia</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>34</volume>
            <issue>9</issue>
            <fpage>645</fpage>
            <page-range>645-655</page-range>
            <pub-id pub-id-type="pmid">24558185</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93576.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baraldi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pellesi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Guerzoni</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cainazzo</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Pini</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Therapeutical approaches to paroxysmal hemicrania, hemicrania continua and short lasting unilateral neuralgiform headache attacks: a critical appraisal.</article-title>
            <source>J Headache Pain</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>71</fpage>
            <pub-id pub-id-type="pmid">28730562</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93576.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Biglione</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gitin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gorelick</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Hennekens</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Aspirin in the Treatment and Prevention of Migraine Headaches: Possible Additional Clinical Options for Primary Healthcare Providers.</article-title>
            <source>Am J Med</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>133</volume>
            <issue>4</issue>
            <fpage>412</fpage>
            <page-range>412-416</page-range>
            <pub-id pub-id-type="pmid">31712099</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93576.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lipton</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Munjal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Brand-Schieber</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tepper</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Dodick</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>Efficacy, Tolerability, and Safety of DFN-15 (Celecoxib Oral Solution, 25 mg/mL) in the Acute Treatment of Episodic Migraine: A Randomized, Double-Blind, Placebo-Controlled Study.</article-title>
            <source>Headache</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>60</volume>
            <issue>1</issue>
            <fpage>58</fpage>
            <page-range>58-70</page-range>
            <pub-id pub-id-type="pmid">31647577</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93576.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wiffen</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Knaggs</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Derry</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cole</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Paracetamol (acetaminophen) with or without codeine or dihydrocodeine for neuropathic pain in adults.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2016</year>
            <month>Dec</month>
            <day>27</day>
            <volume>12</volume>
            <issue>12</issue>
            <fpage>CD012227</fpage>
            <pub-id pub-id-type="pmid">28027389</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93576.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Derry</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Derry</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Sumatriptan (all routes of administration) for acute migraine attacks in adults - overview of Cochrane reviews.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2014</year>
            <month>May</month>
            <day>28</day>
            <volume>2014</volume>
            <issue>5</issue>
            <fpage>CD009108</fpage>
            <pub-id pub-id-type="pmid">24865446</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93576.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Derry</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Derry</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Sumatriptan (intranasal route of administration) for acute migraine attacks in adults.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2012</year>
            <month>Feb</month>
            <day>15</day>
            <volume>2012</volume>
            <issue>2</issue>
            <fpage>CD009663</fpage>
            <pub-id pub-id-type="pmid">22336867</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93576.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Havanka</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Dahl&#x000f6;f</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pop</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Diener</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Winter</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Whitehouse</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hassani</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of naratriptan tablets in the acute treatment of migraine: a dose-ranging study. Naratriptan S2WB2004 Study Group.</article-title>
            <source>Clin Ther</source>
            <year>2000</year>
            <month>Aug</month>
            <volume>22</volume>
            <issue>8</issue>
            <fpage>970</fpage>
            <page-range>970-80</page-range>
            <pub-id pub-id-type="pmid">10972633</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93576.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rapoport</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Ramadan</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Adelman</surname>
                <given-names>JU</given-names>
              </name>
              <name>
                <surname>Mathew</surname>
                <given-names>NT</given-names>
              </name>
              <name>
                <surname>Elkind</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Kudrow</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Earl</surname>
                <given-names>NL</given-names>
              </name>
            </person-group>
            <article-title>Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group.</article-title>
            <source>Neurology</source>
            <year>1997</year>
            <month>Nov</month>
            <volume>49</volume>
            <issue>5</issue>
            <fpage>1210</fpage>
            <page-range>1210-8</page-range>
            <pub-id pub-id-type="pmid">9371896</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93576.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goadsby</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Zanchin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Geraud</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>de Klippel</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Diaz-Insa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gobel</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Cunha</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ivanoff</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Falques</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fortea</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Early vs. non-early intervention in acute migraine-'Act when Mild (AwM)'. A double-blind, placebo-controlled trial of almotriptan.</article-title>
            <source>Cephalalgia</source>
            <year>2008</year>
            <month>Apr</month>
            <volume>28</volume>
            <issue>4</issue>
            <fpage>383</fpage>
            <page-range>383-91</page-range>
            <pub-id pub-id-type="pmid">18294251</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93576.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Oldman</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>McQuay</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Eletriptan for acute migraine.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2001</year>
            <issue>3</issue>
            <fpage>CD003224</fpage>
            <pub-id pub-id-type="pmid">11687056</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93576.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kelley</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Tepper</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>Rescue therapy for acute migraine, part 2: neuroleptics, antihistamines, and others.</article-title>
            <source>Headache</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>52</volume>
            <issue>2</issue>
            <fpage>292</fpage>
            <page-range>292-306</page-range>
            <pub-id pub-id-type="pmid">22309235</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93576.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Croop</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Goadsby</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Stock</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Conway</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Forshaw</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stock</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Coric</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Lipton</surname>
                <given-names>RB</given-names>
              </name>
            </person-group>
            <article-title>Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial.</article-title>
            <source>Lancet</source>
            <year>2019</year>
            <month>Aug</month>
            <day>31</day>
            <volume>394</volume>
            <issue>10200</issue>
            <fpage>737</fpage>
            <page-range>737-745</page-range>
            <pub-id pub-id-type="pmid">31311674</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93576.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lipton</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Dodick</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Ailani</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Finnegan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Szegedi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Trugman</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial.</article-title>
            <source>JAMA</source>
            <year>2019</year>
            <month>Nov</month>
            <day>19</day>
            <volume>322</volume>
            <issue>19</issue>
            <fpage>1887</fpage>
            <page-range>1887-1898</page-range>
            <pub-id pub-id-type="pmid">31742631</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93576.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goadsby</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Wietecha</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Dennehy</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Kuca</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Case</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Aurora</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Gaul</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine.</article-title>
            <source>Brain</source>
            <year>2019</year>
            <month>Jul</month>
            <day>01</day>
            <volume>142</volume>
            <issue>7</issue>
            <fpage>1894</fpage>
            <page-range>1894-1904</page-range>
            <pub-id pub-id-type="pmid">31132795</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93576.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Winner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Aurora</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Jeleva</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hocevar-Trnka</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shrewsbury</surname>
                <given-names>SB</given-names>
              </name>
            </person-group>
            <article-title>STOP 301: A Phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD<sup>&#x000ae;</sup> ) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients.</article-title>
            <source>Headache</source>
            <year>2021</year>
            <month>Sep</month>
            <volume>61</volume>
            <issue>8</issue>
            <fpage>1214</fpage>
            <page-range>1214-1226</page-range>
            <pub-id pub-id-type="pmid">34363701</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93576.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Modi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lowder</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Medications for migraine prophylaxis.</article-title>
            <source>Am Fam Physician</source>
            <year>2006</year>
            <month>Jan</month>
            <day>01</day>
            <volume>73</volume>
            <issue>1</issue>
            <fpage>72</fpage>
            <page-range>72-8</page-range>
            <pub-id pub-id-type="pmid">16417067</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93576.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pringsheim</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Davenport</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>Prophylaxis of migraine headache.</article-title>
            <source>CMAJ</source>
            <year>2010</year>
            <month>Apr</month>
            <day>20</day>
            <volume>182</volume>
            <issue>7</issue>
            <fpage>E269</fpage>
            <page-range>E269-76</page-range>
            <pub-id pub-id-type="pmid">20159899</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93576.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Markley</surname>
                <given-names>HG</given-names>
              </name>
            </person-group>
            <article-title>Verapamil and migraine prophylaxis: mechanisms and efficacy.</article-title>
            <source>Am J Med</source>
            <year>1991</year>
            <month>May</month>
            <day>17</day>
            <volume>90</volume>
            <issue>5A</issue>
            <fpage>48S</fpage>
            <page-range>48S-53S</page-range>
            <pub-id pub-id-type="pmid">2039020</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
